New hope for Tough-to-Treat amyloidosis: testing a powerful drug trio
NCT ID NCT04270175
Summary
This study is testing whether adding a drug called pomalidomide to two other medications (daratumumab and dexamethasone) works better for people with AL amyloidosis that has come back or stopped responding to prior treatment. It is for patients who have already received daratumumab before. The main goal is to see if this three-drug combination leads to a deeper and more lasting remission of the disease compared to older treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston University Medical Center
Boston, Massachusetts, 02118, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Weill Cornell Medicine - Multiple Myeloma Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.